CA3254503A1 - PURE FORMS OF CRYSTALLINE ATICAPRANT - Google Patents
PURE FORMS OF CRYSTALLINE ATICAPRANTInfo
- Publication number
- CA3254503A1 CA3254503A1 CA3254503A CA3254503A CA3254503A1 CA 3254503 A1 CA3254503 A1 CA 3254503A1 CA 3254503 A CA3254503 A CA 3254503A CA 3254503 A CA3254503 A CA 3254503A CA 3254503 A1 CA3254503 A1 CA 3254503A1
- Authority
- CA
- Canada
- Prior art keywords
- aticaprant
- composition
- treatment
- crystalline form
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| US63/317,483 | 2022-03-07 | ||
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254503A1 true CA3254503A1 (en) | 2023-09-14 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254503A Pending CA3254503A1 (en) | 2022-03-07 | 2023-03-06 | PURE FORMS OF CRYSTALLINE ATICAPRANT |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (OSRAM) |
| EP (1) | EP4489748A1 (OSRAM) |
| JP (1) | JP2025508071A (OSRAM) |
| KR (1) | KR20240158951A (OSRAM) |
| CN (1) | CN119156210A (OSRAM) |
| AU (1) | AU2023231493A1 (OSRAM) |
| CA (1) | CA3254503A1 (OSRAM) |
| CL (1) | CL2024002643A1 (OSRAM) |
| CO (1) | CO2024012457A2 (OSRAM) |
| IL (1) | IL315411A (OSRAM) |
| JO (1) | JOP20240195A1 (OSRAM) |
| MX (1) | MX2024010978A (OSRAM) |
| PE (1) | PE20242109A1 (OSRAM) |
| TW (1) | TW202345795A (OSRAM) |
| WO (1) | WO2023170547A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| TW202400135A (zh) | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| KR20240004857A (ko) * | 2021-05-04 | 2024-01-11 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
-
2023
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119156210A (zh) | 2024-12-17 |
| US20230348377A1 (en) | 2023-11-02 |
| EP4489748A1 (en) | 2025-01-15 |
| IL315411A (en) | 2024-11-01 |
| JP2025508071A (ja) | 2025-03-21 |
| US20250326714A1 (en) | 2025-10-23 |
| AU2023231493A1 (en) | 2024-10-24 |
| MX2024010978A (es) | 2024-12-06 |
| JOP20240195A1 (ar) | 2024-09-05 |
| KR20240158951A (ko) | 2024-11-05 |
| PE20242109A1 (es) | 2024-10-28 |
| CO2024012457A2 (es) | 2024-09-30 |
| TW202345795A (zh) | 2023-12-01 |
| WO2023170547A1 (en) | 2023-09-14 |
| CL2024002643A1 (es) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230348377A1 (en) | Pure forms of crystalline aticaprant | |
| US11266627B1 (en) | Compositions and methods for the treatment of depression | |
| CA3219079A1 (en) | Compositions and methods for the treatment of depression | |
| US12419859B2 (en) | Compositions and methods for the treatment of depression | |
| US12201610B2 (en) | Compositions comprising aticaprant | |
| US20250325515A1 (en) | Forms Of Aticaprant | |
| WO2023131920A1 (en) | Compositions and methods for the treatment of depression | |
| WO2025052301A1 (en) | Compositions comprising aticaprant for use in treating major depressive disorder | |
| EA050800B1 (ru) | Композиции и способы лечения депрессии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240905 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250204 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250206 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250206 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250224 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260505 |